glp 1 receptor structure The Extracellular Surface of the GLP-1 Is a Molecular Trigger for Biased Agonism: Cell Glucagon-like peptide-1 - Wikipedia

Verify current availability and legal status with your provider and dispensing pharmacy before assuming these options are accessible

This suggested that GLP-1 resistance existed in the diabetic lean model

This can lead to weight loss

Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions

Endocrinology 157 , 16601672 (2016)

Long-term safety data is still limited, and the novel glucagon-agonist component introduces uncertainties about long-term effects